Use of ibogamine congeners for treating obesity

Details Use of ibogamine congeners for treating obesity Use of ibogamine congeners for treating obesity

A - Human Necessities

61

K

A61K 31/55 (2006.01) A61P 3/04 (2006.01) C07D 487/14 (2006.01)

Patent

CA 2712553

The present invention relates to a method of treating obesity in a subject by administering to the subject a com-pound having the formula (I) wherein n is from 0 to 8; R1 is CH2OH, CH(OH)R5, CH2OR5, CO2R5, C(O)NH2, C(O)NHR5, C(O)NR5R6, C(O)NHNH2, C(O)NHNHR5, C(O)NHNR5R6, C(O)NR5NH2, C(O)NR5NHR6, C(O)NR5NR6R7, C(O)NHNH(C(O)R5), C(O)NHNR5(C(O)R6), C(O)NR5NH(C(O)R6), C(O)NR5NR6(C(O)R7), CN, or C(O)R5; R2 is H, unsub-stituted or substituted alkyl, YH, YR8, YR8R9, YR8YR9YR10, YC(O)R8, C(O)YR8, C(O)NH2, C(O)NHR8, C(O)NR8R9, NH2, NHR8, NR8R9, NHC(O)R8, or NR8C(O)R9; R3 and R4 are the same or different and are selected from the group consist-ing of H, halogens, unsubstituted or substituted alkyl, OH, OR10, NH2, NHR10, NR10R11, NHC(O)R10, or NR10C(O)R11; R5, R6, R7, R8, R9, R10, and R11 are the same or different and are selected from the group consisting of H, unsubstituted alkyl, substituted alkyl, unsubstituted aryl and substituted aryl; R12 is selected from the group consisting of H, unsubstituted alkyl, and substituted alkyl; and Y is O or S; and pharmaceutically acceptable salts thereof.

La présente invention concerne un procédé de traitement de l'obésité chez un sujet par l'administration au sujet d'un composé de formule (I) dans lequel n vaut de 0 à 8 ; R1 est CH2OH, CH(OH)R5, CH2OR5, CO2R5, C(O)NH2, C(O)NHR5, C(O)NR5R6, C(O)NHNH2, C(O)NHNHR5, C(O)NHNR5R6, C(O)NR5NH2, C(O)NR5NHR6, C(O)NR5NR6R7, C(O)NHNH(C(O)R5), C(O)NHNR5(C(O)R6), C(O)NR5NH(C(O)R6), C(O)NR5NR6(C(O)R7), CN, ou C(O)R5 ; R2 est H, un groupe alkyle substitué ou non substitué, YH, YR8, YR8R9, YR8YR9YR10, YC(O)R8, C(O)YR8, C(O)NH2, C(O)NHR8, C(O)NR8R9, NH2, NHR8, NR8R9, NHC(O)R8, ou NR8C(O)R9 ; R3 et R4 sont identiques ou différents et sont choisis dans le groupe comprenant, des atomes d'halogène, un groupe alkyle substitué ou non substitué, OH, OR10, NH2, NHR10, NR10R11, NHC(O)R10, ou NR10C(O)R11 ; R5, R6, R7, R8, R9, R10, et R11 sont identiques ou différents et sont choisis dans le groupe comprenant H, un groupe alkyle non substitué, un groupe alkyle substitué, un groupe aryle non substitué et un groupe aryle substitué ; R12 est choisi dans le groupe comprenant H, un groupe alkyle non substitué, et alkyle substitué ; et Y est O ou S ; et des sels pharmaceutiquement acceptables de ceux-ci.

Affiliated with

Also associated with

Rating

Use of ibogamine congeners for treating obesity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of ibogamine congeners for treating obesity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of ibogamine congeners for treating obesity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1832012